Antisense and Gene Therapy Options for Duchenne Muscular Dystrophy Arising from Mutations in the N-Terminal Hotspot

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2022 Feb 25

PMID 35205302

Authors

Harry Wilton-Clark

Toshifumi Yokota

Affiliations

Soon will be listed here.

Abstract

Duchenne muscular dystrophy (DMD) is a fatal genetic disease affecting children that is caused by a mutation in the gene encoding for dystrophin. In the absence of functional dystrophin, patients experience progressive muscle deterioration, leaving them wheelchair-bound by age 12 and with few patients surviving beyond their third decade of life as the disease advances and causes cardiac and respiratory difficulties. In recent years, an increasing number of antisense and gene therapies have been studied for the treatment of muscular dystrophy; however, few of these therapies focus on treating mutations arising in the N-terminal encoding region of the dystrophin gene. This review summarizes the current state of development of N-terminal antisense and gene therapies for DMD, mainly focusing on exon-skipping therapy for duplications and deletions, as well as microdystrophin therapy.

Citing Articles

Unveiling the Future of Cardiac Care: A Review of Gene Therapy in Cardiomyopathies.

Venturiello D, Tiberi P, Perulli F, Nardoianni G, Guida L, Barsali C Int J Mol Sci. 2024; 25(23).

PMID: 39684857 PMC: 11642060. DOI: 10.3390/ijms252313147.

Golodirsen restores DMD transcript imbalance in Duchenne Muscular Dystrophy patient muscle cells.

Rossi R, Torelli S, Moore M, Ala P, Morgan J, Malhotra J Skelet Muscle. 2024; 14(1):28.

PMID: 39614336 PMC: 11606086. DOI: 10.1186/s13395-024-00360-4.

Oligonucleotide therapeutics in sports? An antidoping perspective.

Parr M, Keiler A Arch Pharm (Weinheim). 2024; 358(1):e2400404.

PMID: 39449227 PMC: 11704058. DOI: 10.1002/ardp.202400404.

Correction of exon 2, exon 2-9 and exons 8-9 duplications in DMD patient myogenic cells by a single CRISPR/Cas9 system.

Lemoine J, Dubois A, Dorval A, Jaber A, Warthi G, Mamchaoui K Sci Rep. 2024; 14(1):21238.

PMID: 39261505 PMC: 11390959. DOI: 10.1038/s41598-024-70075-5.

Comprehensive review of adverse reactions and toxicology in ASO-based therapies for Duchenne Muscular Dystrophy: From FDA-approved drugs to peptide-conjugated ASO.

Haque U, Kohut M, Yokota T Curr Res Toxicol. 2024; 7:100182.

PMID: 38983605 PMC: 11231654. DOI: 10.1016/j.crtox.2024.100182.

References

Birnkrant D, Bushby K, Bann C, Apkon S, Blackwell A, Brumbaugh D . Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018; 17(3):251-267. PMC: 5869704. DOI: 10.1016/S1474-4422(18)30024-3. View

Gushchina L, Frair E, Rohan N, J Bradley A, Simmons T, Chavan H . Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce Exon 2 Skipping. Hum Gene Ther. 2021; 32(17-18):882-894. PMC: 10112461. DOI: 10.1089/hum.2020.286. View

Lee J, Yokota T . Antisense therapy in neurology. J Pers Med. 2015; 3(3):144-76. PMC: 4251390. DOI: 10.3390/jpm3030144. View

Duan D . Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients. Hum Gene Ther. 2018; 29(7):733-736. PMC: 6066190. DOI: 10.1089/hum.2018.012. View

Nakamura A, Fueki N, Shiba N, Motoki H, Miyazaki D, Nishizawa H . Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy. J Hum Genet. 2016; 61(7):663-7. DOI: 10.1038/jhg.2016.28. View

Lakhia R, Mishra A, Patel V . Manipulation of renal gene expression using oligonucleotides. Methods Cell Biol. 2019; 154:109-120. PMC: 7992197. DOI: 10.1016/bs.mcb.2019.05.006. View

Echigoya Y, Aoki Y, Miskew B, Panesar D, Touznik A, Nagata T . Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucleic Acids. 2015; 4:e225. PMC: 4345310. DOI: 10.1038/mtna.2014.76. View

Okubo M, Noguchi S, Hayashi S, Nakamura H, Komaki H, Matsuo M . Exon skipping induced by nonsense/frameshift mutations in DMD gene results in Becker muscular dystrophy. Hum Genet. 2020; 139(2):247-255. PMC: 6981323. DOI: 10.1007/s00439-019-02107-4. View

Naso M, Tomkowicz B, Perry 3rd W, Strohl W . Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs. 2017; 31(4):317-334. PMC: 5548848. DOI: 10.1007/s40259-017-0234-5. View

10.

Godfrey C, Desviat L, Smedsrod B, Pietri-Rouxel F, Denti M, Disterer P . Delivery is key: lessons learnt from developing splice-switching antisense therapies. EMBO Mol Med. 2017; 9(5):545-557. PMC: 5412803. DOI: 10.15252/emmm.201607199. View

11.

Pattali R, Mou Y, Li X . AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy. Gene Ther. 2019; 26(7-8):287-295. DOI: 10.1038/s41434-019-0085-4. View

12.

Colella P, Ronzitti G, Mingozzi F . Emerging Issues in AAV-Mediated Gene Therapy. Mol Ther Methods Clin Dev. 2018; 8:87-104. PMC: 5758940. DOI: 10.1016/j.omtm.2017.11.007. View

13.

Wang D, Tai P, Gao G . Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019; 18(5):358-378. PMC: 6927556. DOI: 10.1038/s41573-019-0012-9. View

14.

Nowak K, Davies K . Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep. 2004; 5(9):872-6. PMC: 1299132. DOI: 10.1038/sj.embor.7400221. View

15.

Neri M, Rossi R, Trabanelli C, Mauro A, Selvatici R, Falzarano M . The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study. Front Genet. 2020; 11:131. PMC: 7063120. DOI: 10.3389/fgene.2020.00131. View

16.

Yue Y, Pan X, Hakim C, Kodippili K, Zhang K, Shin J . Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. Hum Mol Genet. 2015; 24(20):5880-90. PMC: 4581611. DOI: 10.1093/hmg/ddv310. View

17.

Mendell J, Sahenk Z, Lehman K, Nease C, Lowes L, Miller N . Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial. JAMA Neurol. 2020; 77(9):1122-1131. PMC: 7296461. DOI: 10.1001/jamaneurol.2020.1484. View

18.

Philippidis A . After Third Death, Audentes' AT132 Remains on Clinical Hold. Hum Gene Ther. 2020; 31(17-18):908-910. DOI: 10.1089/hum.2020.29133.bfs. View

19.

Gardner-Medwin D . Clinical features and classification of the muscular dystrophies. Br Med Bull. 1980; 36(2):109-15. DOI: 10.1093/oxfordjournals.bmb.a071623. View

20.

Wein N, Vulin A, Falzarano M, Szigyarto C, Maiti B, Findlay A . Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice. Nat Med. 2014; 20(9):992-1000. PMC: 4165597. DOI: 10.1038/nm.3628. View